Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
NCT ID: NCT01917578
Last Updated: 2013-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
4 participants
INTERVENTIONAL
2008-08-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Half Cycles Group
Patients complete half of the whole cycles of neoadjuvant chemotherapy.
Ultrasound
1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size refers to WHO standards.
CNB
Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
BCS, Modified Radical Mastectomy
All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
Pathologic Large Tissue Selected Table
1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.
2. Each piece of breast tissues by cutting with the table has 3mm thickness.
Leica TP1020
Procedure:
1. Alcohol 70 % 1h
2. Alcohol 80 % 1h
3. Alcohol 85 % 1h
4. Alcohol 90 % 1h
5. Alcohol 95 % 1h
6. Alcohol Ⅰ 100 % 1h
7. Alcohol Ⅱ 100 % 1h
8. Xylene Ⅰ 2h
9. Xylene Ⅱ 2h
10. Xylene Ⅲ 2h
11. Paraffin 6h
12. Paraffin 6h
Pathologic Large Tissue Embedded Table
1. The table is made of brass .It is applying for a chinese patent.
2. The table can simultaneously embed 8 piece of breast tissues.
Leica SM2000 R
Each of paraffin section has 4 um thickness.
HE Stain
Procedure:
1. Xylene Ⅰ 60℃ 15-20 minutes
2. Xylene Ⅱ 60℃ 15-20 minutes
3. Alcohol 100% Ⅰ 3-5 minutes
4. Alcohol 100% Ⅱ 3-5 minutes
5. Alcohol 95% Ⅱ 3-5 minutes
6. Alcohol 90% Ⅱ 3-5 minutes
7. Wash in running tap water for 3 minutes
8. Hematoxylin 5-10 minutes
9. Wash in running tap water for 3 minutes
10. Differentiate in 1% acid alcohol for 30 seconds
11. Wash in running tap water for 1 minute
12. Bluing in 0.2% ammonia water for 30-60 seconds
13. Wash in running tap water for 3 minutes
14. Counterstain in eosin Y solution for 30-60 seconds
15. Wash in running tap water for 1 minute
16. Alcohol 90% Ⅱ 2-3 minutes
17. Alcohol 95% Ⅱ 2-3 minutes
18. Alcohol 100% Ⅱ 3-5 minutes
19. Alcohol 100% Ⅱ 3-5 minutes
20. Xylene Ⅲ 5-10 minutes
21. Xylene Ⅳ 5-10 minutes
22. Mounting with neutral resin
CX22
The residual tumor areas are microscopically outlined on each slice by pathologist.
Epson V600
1. Each slice that has been microscopically outlined is scanned by Epson V600.
2. Every image by scanning should be saved as JPG.
Three-Dimensional Reconstruction
A.Pathological images three-dimensional reconstruction:
1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.
2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.
3. Observe the shrinkage modes in three-dimensional space.
4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.
5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.
B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction
Mammography
1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size and calcification extent refers to WHO standards.
3. Calcification extent is not only measured in mammography image but also under microscope.
TAC,TC,TA,CAF,CEF
1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)
2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)
3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)
4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
Whole Cycles Group
Patients complete whole cycles of neoadjuvant chemotherapy.
Ultrasound
1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size refers to WHO standards.
CNB
Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
BCS, Modified Radical Mastectomy
All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
Pathologic Large Tissue Selected Table
1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.
2. Each piece of breast tissues by cutting with the table has 3mm thickness.
Leica TP1020
Procedure:
1. Alcohol 70 % 1h
2. Alcohol 80 % 1h
3. Alcohol 85 % 1h
4. Alcohol 90 % 1h
5. Alcohol 95 % 1h
6. Alcohol Ⅰ 100 % 1h
7. Alcohol Ⅱ 100 % 1h
8. Xylene Ⅰ 2h
9. Xylene Ⅱ 2h
10. Xylene Ⅲ 2h
11. Paraffin 6h
12. Paraffin 6h
Pathologic Large Tissue Embedded Table
1. The table is made of brass .It is applying for a chinese patent.
2. The table can simultaneously embed 8 piece of breast tissues.
Leica SM2000 R
Each of paraffin section has 4 um thickness.
HE Stain
Procedure:
1. Xylene Ⅰ 60℃ 15-20 minutes
2. Xylene Ⅱ 60℃ 15-20 minutes
3. Alcohol 100% Ⅰ 3-5 minutes
4. Alcohol 100% Ⅱ 3-5 minutes
5. Alcohol 95% Ⅱ 3-5 minutes
6. Alcohol 90% Ⅱ 3-5 minutes
7. Wash in running tap water for 3 minutes
8. Hematoxylin 5-10 minutes
9. Wash in running tap water for 3 minutes
10. Differentiate in 1% acid alcohol for 30 seconds
11. Wash in running tap water for 1 minute
12. Bluing in 0.2% ammonia water for 30-60 seconds
13. Wash in running tap water for 3 minutes
14. Counterstain in eosin Y solution for 30-60 seconds
15. Wash in running tap water for 1 minute
16. Alcohol 90% Ⅱ 2-3 minutes
17. Alcohol 95% Ⅱ 2-3 minutes
18. Alcohol 100% Ⅱ 3-5 minutes
19. Alcohol 100% Ⅱ 3-5 minutes
20. Xylene Ⅲ 5-10 minutes
21. Xylene Ⅳ 5-10 minutes
22. Mounting with neutral resin
CX22
The residual tumor areas are microscopically outlined on each slice by pathologist.
Epson V600
1. Each slice that has been microscopically outlined is scanned by Epson V600.
2. Every image by scanning should be saved as JPG.
MRI
1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size refers to WHO standards.
3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction.
Three-Dimensional Reconstruction
A.Pathological images three-dimensional reconstruction:
1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.
2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.
3. Observe the shrinkage modes in three-dimensional space.
4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.
5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.
B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction
Mammography
1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size and calcification extent refers to WHO standards.
3. Calcification extent is not only measured in mammography image but also under microscope.
AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF
1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.
2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)
3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)
4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)
5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.
6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound
1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size refers to WHO standards.
CNB
Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
BCS, Modified Radical Mastectomy
All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
Pathologic Large Tissue Selected Table
1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.
2. Each piece of breast tissues by cutting with the table has 3mm thickness.
Leica TP1020
Procedure:
1. Alcohol 70 % 1h
2. Alcohol 80 % 1h
3. Alcohol 85 % 1h
4. Alcohol 90 % 1h
5. Alcohol 95 % 1h
6. Alcohol Ⅰ 100 % 1h
7. Alcohol Ⅱ 100 % 1h
8. Xylene Ⅰ 2h
9. Xylene Ⅱ 2h
10. Xylene Ⅲ 2h
11. Paraffin 6h
12. Paraffin 6h
Pathologic Large Tissue Embedded Table
1. The table is made of brass .It is applying for a chinese patent.
2. The table can simultaneously embed 8 piece of breast tissues.
Leica SM2000 R
Each of paraffin section has 4 um thickness.
HE Stain
Procedure:
1. Xylene Ⅰ 60℃ 15-20 minutes
2. Xylene Ⅱ 60℃ 15-20 minutes
3. Alcohol 100% Ⅰ 3-5 minutes
4. Alcohol 100% Ⅱ 3-5 minutes
5. Alcohol 95% Ⅱ 3-5 minutes
6. Alcohol 90% Ⅱ 3-5 minutes
7. Wash in running tap water for 3 minutes
8. Hematoxylin 5-10 minutes
9. Wash in running tap water for 3 minutes
10. Differentiate in 1% acid alcohol for 30 seconds
11. Wash in running tap water for 1 minute
12. Bluing in 0.2% ammonia water for 30-60 seconds
13. Wash in running tap water for 3 minutes
14. Counterstain in eosin Y solution for 30-60 seconds
15. Wash in running tap water for 1 minute
16. Alcohol 90% Ⅱ 2-3 minutes
17. Alcohol 95% Ⅱ 2-3 minutes
18. Alcohol 100% Ⅱ 3-5 minutes
19. Alcohol 100% Ⅱ 3-5 minutes
20. Xylene Ⅲ 5-10 minutes
21. Xylene Ⅳ 5-10 minutes
22. Mounting with neutral resin
CX22
The residual tumor areas are microscopically outlined on each slice by pathologist.
Epson V600
1. Each slice that has been microscopically outlined is scanned by Epson V600.
2. Every image by scanning should be saved as JPG.
MRI
1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size refers to WHO standards.
3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction.
Three-Dimensional Reconstruction
A.Pathological images three-dimensional reconstruction:
1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.
2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.
3. Observe the shrinkage modes in three-dimensional space.
4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.
5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.
B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction
Mammography
1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.
2. Measurement of tumor size and calcification extent refers to WHO standards.
3. Calcification extent is not only measured in mammography image but also under microscope.
TAC,TC,TA,CAF,CEF
1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)
2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)
3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)
4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF
1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.
2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)
3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)
4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)
5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.
6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed invasive adenocarcinoma of the breast.
3. Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). (T1N0M0 lesions are excluded.)
4. Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are acceptable. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. This will need to be re-evaluated after 3 cycles and prior to surgery.
5. ECOG 0 or 2
6. No distant metastasis, as documented by complete staging workup ≤6 weeks prior to initiation of study treatment.
7. No previous treatment for breast cancer.
8. Adequate hematologic function with:
Absolute neutrophil count (ANC) \>1500/μL. Platelets ≥100,000/μL. Hemoglobin ≥10 g/dL.
9. Adequate hepatic function with:
Serum bilirubin ≤ the institutional upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤2.5 x institutional ULN. Alanine aminotransferase (ALT) ≤2.5 x institutional ULN.
10. Adequate renal function with serum creatinine ≤1.5 x ULN.
11. Planned primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant chemotherapy
Exclusion Criteria
2. Pregnancy or breast-feeding.A negative serum pregnancy test within 7 days prior to first study treatment (Day 1, Cycle 1) for all women of childbearing potential is required. Patients of childbearing potential must agree to use a birth control method that is approved by their study physician while receiving study treatment and for 3 weeks after their last dose of study treatment. Patients must agree to not breast-feed while receiving study treatment.
3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment.
4. Uncontrolled intercurrent illness including (but not limited to) ongoing or active infection.
5. Concurrent treatment with any anti-cancer therapy other than those agents used in this study.
6. Mental condition or psychiatric disorder that would prevent patient comprehension of the nature, scope, and possible consequences of the study or that would limit compliance with study requirements.
18 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Cancer Hospital and Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongsheng Wang
Director, Head of Breast Cancer Center, Principal Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yong-sheng Wang, MD
Role: STUDY_CHAIR
Shandong Cancer Hospital and Institute
Tao Yang, MD
Role: PRINCIPAL_INVESTIGATOR
Shandong Cancer Hospital and Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong Cancer Hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yong-sheng Wang, MD
Role: primary
Tao Yang, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Y-S Wang, Z-P Zhang, G Liu, D-B Mu, and X-Y Sun.Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction. Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCSMANC001
Identifier Type: -
Identifier Source: org_study_id